Expression of ERAP1 in patients with hepatocellular carcinoma and its correlation with prognosis
10.19405/j.cnki.issn1000-1492.2022.12.010
- Author:
Huanhuan Liu
1
;
Xingyu Fan
1
;
Ying Yang
1
;
Qin Wang
1
;
Hao Zhang
1
;
Faming Pan
2
;
Liwen Chen
1
Author Information
1. Dept of Clinical Laboratory Medicine，The Second Hospital of Anhui Medical University，Hefei 230601
2. School of Public Health，Anhui Medical University，Hefei 230032
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
endoplasmic reticulum aminopeptidase-1;
severity;
prognosis;
diagnosis
- From:
Acta Universitatis Medicinalis Anhui
2022;57(12):1902-1907
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To investigate the diagnostic endoplasmic reticulum aminopeptidase-1 (ERAP1) in patients with hepatocellular carcinomae (HCC) ．
Methods :Enzyme-linked immunosorbent assay (ELISA) was used to de- tect the serum levels of ERAP1 in HCCpatients，cirrhosis patients and healthy controls (HC) ．Multivariate logistic regression was used to analyze the independent risk factors of the severity and prognosis ，and receiver operating characteristic curve (ROC) was used to evaluatesensitivity and specificity of ERAP1 in the diagnosis of different degree of disease and prognosis.
Results :The serum ERAP1 level of HCC was related to tumor stage，tumor size and number of cancer focal (P ＜0. 05 ) ． ERAP1 level of HCC patients was positivecorrelated with ALT ，AST， TBIL and AFP，while negative correlated with ALB(P＜0. 05) ．ERAP1 was found to be an independent predictor of different severity and prognosis．When joint diagnosing HCC with AFP，the area under the curve ( AUC) was 0. 932．For the diagnosis of poor prognosis，the AUC was 0. 742．
Conclusion :Serum ERAP1 level has important clinical significance and potential application value in evaluating the severity and prognosis of HCC patients.
- Full text:2024072115580041857内质网氨肽酶-1在HCC中的表达及预后的相关性研究_刘欢欢.pdf
